Copper metabolism, as a new therapeutic biomarker and a potential target for radionuclide therapy in HCC, has potential applications in molecular imaging and targeted therapy of HCC, besides copper chelators or human copper transporter 1 (hCTR1) specific short-interference RNA that blocking copper absorption could be used to inhibit the growth of HCC in the therapy of copper regulation (47). Here, SLC31A1 is linked to hepatocellular carcinoma.